Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 316

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 316
---
 paragraph related to the substantial doubt about PBAX’s ability
to continue as a going concern. Such financial statements are included in reliance upon the report of such firm as experts in accounting
and auditing.

The financial statements
of CERo Therapeutics, Inc. as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023, included
in this prospectus have been audited by Wolf & Company, P.C., an independent registered public accounting firm, as stated in their
report. Such financial statements are included in reliance upon such report given on the authority of such firm as experts in accounting
and auditing.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed a registration
statement on Form S-1, including exhibits, under the Securities Act with respect to the shares of our Common Stock offered by this prospectus.
This prospectus constitutes only a part of the registration statement. Some items are contained in exhibits to the registration statement
as permitted by the rules and regulations of the SEC. For further information with respect to us and our securities, we refer you to
the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus
concerning the contents of any contract or document referred to are not necessarily complete. If a contract or document has been filed
as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this
prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit.

In addition, we file annual,
quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a
website maintained by the SEC located at www.sec.gov.We also maintain a website at www.cero.bio/investors.Through our
website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as
reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may
be accessed through, our website is not part of, and is not incorporated into, this prospectus. Information contained on our website
is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses
in this prospectus is an